Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $6
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsUpgradesPrice Target
Wells Fargo analyst Yanan Zhu upgrades Editas Medicine (NASDAQ:EDIT) from Equal-Weight to Overweight and raises the price target from $4 to $6.
Wells Fargo analyst Yanan Zhu upgrades Editas Medicine (NASDAQ:EDIT) from Equal-Weight to Overweight and raises the price target from $4 to $6.